Compare KRT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRT | IMMX |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Plastic Products | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.4M | 629.3M |
| IPO Year | 2019 | 2021 |
| Metric | KRT | IMMX |
|---|---|---|
| Price | $27.19 | $8.83 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $26.50 | $19.20 |
| AVG Volume (30 Days) | 94.0K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 4.70 | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $467,743,000.00 | N/A |
| Revenue This Year | $13.05 | N/A |
| Revenue Next Year | $8.11 | N/A |
| P/E Ratio | $80.50 | ★ N/A |
| Revenue Growth | ★ 10.67 | N/A |
| 52 Week Low | $20.61 | $1.87 |
| 52 Week High | $32.06 | $11.61 |
| Indicator | KRT | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 42.84 |
| Support Level | $26.95 | $8.10 |
| Resistance Level | $30.82 | $8.97 |
| Average True Range (ATR) | 0.88 | 0.72 |
| MACD | -0.03 | -0.11 |
| Stochastic Oscillator | 55.77 | 27.31 |
Karat Packaging Inc is a distributor and manufacturer of disposable foodservice products and related items, including containers, bags, tableware, cups, lids, cutlery, straws, specialty beverage ingredients, gloves, and janitorial supplies, available in plastic, paper, biopolymer-based, and other compostable forms. The Company focuses on environmentally friendly products and provides customized solutions including product development, design, printing, and logistics services. It serves customers through chains and distributors, retail, and e-commerce/online, and operates in the manufacturing and distribution of single-use food and beverage products, as well as specialty food and beverage products and restaurant and warehouse supplies.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.